CDK2 in complex with Cpd14 (5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine)

CDK2 in complex with Cpd14 (5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine) Descriptor: 5-fluoro-N-[5-(4-methylpiperazin-1-yl)pyridin-2-yl]-4-[(4S)-4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl]pyrimidin-2-amine, Cyclin-dependent kinase 2 Authors: Murray, J.M. Deposit date: 2019-04-26 Release date: 2020-07-29 Last modified: 2023-10-11 Method: X-RAY DIFFRACTION (2 Å) Cite: Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma. Bioorg.Med.Chem.Lett., 29, 2019

CDK2与化合物Cpd14（5-氟-4-(4-甲基-5,6,7,8-四氢-4H-吡唑并[1,5-a]氮杂卓-3-基)-N-(5-(4-甲基哌嗪-1-基)吡啶-2-基)嘧啶-2-胺）形成复合物。结构描述：5-氟-N-[5-(4-甲基哌嗪-1-基)吡啶-2-基]-4-[(4S)-4-甲基-5,6,7,8-四氢-4H-吡唑并[1,5-a]氮杂卓-3-基]嘧啶-2-胺，靶标为细胞周期蛋白依赖性激酶2（Cyclin-dependent kinase 2, CDK2）。作者：Murray, J.M.。提交日期：2019-04-26，发布日期：2020-07-29，最后修改日期：2023-10-11。实验方法：X射线衍射（分辨率2 Å）。引用文献：《用于胶质母细胞瘤的可透过血脑屏障的CDK4/6抑制剂的设计》，《Bioorg.Med.Chem.Lett.》，29卷，2019年。